XM does not provide services to residents of the United States of America.
N
N

Novartis


News

Europe before the bell: busy busy

LIVE MARKETS-Europe before the bell: busy busy Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com . EUROPE BEFORE THE BELL: BUSY BUSY There's plenty for investors to digest on Thursday, with earnings from Nvidia overnight and Novartis early Thursday, as well as geopolitics, the latest Trump appointments , bitcoin heading towards $100,000, and Indian billionaire Gautam Adani's indict
C
N
N
P
J
E
F
G

Novartis: launch of Morphosys drug by could be 2027 or later

Novartis: launch of Morphosys drug by could be 2027 or later FRANKFURT, Nov 21 (Reuters) - Novartis' NOVN.S CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data. "It will take us at least until 2027. It might take longer, depending on the safety topic.
N

Swiss stocks - Factors to watch on November 21

Swiss stocks - Factors to watch on November 21 ZURICH/GDANSK, Nov 21 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ZURICH INSURANCE GROUP AG ZURN.S Europe's fifth-largest insurer Zurich Insurance unveiled its targets for the next three years on Thursday, aiming to reach average annual growth of more than 9% in its core earnings per share.
N
S
J
Z
S

Novartis raises sales guidance until 2028

UPDATE 3-Novartis raises sales guidance until 2028 Adds details on Pluvicto, MorphoSys from paragraph 8 By Ludwig Burger FRANKFURT, Nov 21 (Reuters) - Novartis NOVN.S raised its medium-term sales guidance on Thursday to 6% annual growth through 2028, driven by momentum of launched drugs and the prospect of upcoming launches. The Swiss drugmaker was previously targeting mid-term currency-adjusted sales growth of at least 5% from 2023 to 2028. However, the company said it was still expecting 5% sa
N

Novartis raises annual sales guidance until 2028

Novartis raises annual sales guidance until 2028 FRANKFURT, Nov 21 (Reuters) - Novartis NOVN.S on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions. The Swiss drugmaker was previously targeting mid-term currency-adju
N

Vyriad Announces Strategic Collaboration With Novartis To Develop In Vivo Car-T Cell Therapies

BRIEF-Vyriad Announces Strategic Collaboration With Novartis To Develop In Vivo Car-T Cell Therapies Nov 20 (Reuters) - Novartis AG NOVN.S : VYRIAD ANNOUNCES STRATEGIC COLLABORATION WITH NOVARTIS TO DEVELOP IN VIVO CAR-T CELL THERAPIES Source text: ID:nPn8yg4sGa Further company coverage: NOVN.S
N

Swiss trade surplus at CHF 8.063 bln in October

TABLE-Swiss trade surplus at CHF 8.063 bln in October November 19 (Reuters) - Switzerland ran a merchandise trade surplus of 8 .063 billion Swiss francs in October, the Federal Customs Office said on Tuesday. KEY FIGURES (millions of Swiss francs) October 2024 September 2024 Imports 19.681 17.620 Exports 27.745 22.562 Balance 8.063 4.942 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Lilly pill cuts genetic form of cholesterol nearly 86% in study

Lilly pill cuts genetic form of cholesterol nearly 86% in study By Julie Steenhuysen CHICAGO, Nov 18 (Reuters) - The highest dose of an experimental pill developed by Eli Lilly LLY.N dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on Monday. The drug, muvalaplin, reduced levels of lipoprotein(a), or Lp(a), by 70% using a traditional blood test and by nearly 86% based on a more specific test developed by the company
A
N

Ratio Enters License & Collaboration Agreement With Novartis

BRIEF-Ratio Enters License & Collaboration Agreement With Novartis Nov 18 (Reuters) - RATIO THERAPEUTICS INC: TO RECEIVE UP TO $745M IN UPFRONT AND MILESTONE PAYMENTS (CORRECTS SOURCE) ENTERS LICENSE AND COLLABORATION AGREEMENT WITH NOVARTIS FOR SSTR2-TARGETING RADIOTHERAPEUTIC CANDIDATE
N

Alcon cuts 2024 forecasts, as slow US hits surgical unit

Alcon cuts 2024 forecasts, as slow US hits surgical unit By Amir Orusov Nov 13 (Reuters) - Eye-care group Alcon ALCC.S cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business. Alcon, whose biggest market is the U.S. making up nearly a half of its revenue, said it expected annual net sales to grow by 6-7% in constant currency terms, compared to the previous forecast of 7-9%.
J
N

Swiss stocks - Factors to watch on November 4

Swiss stocks - Factors to watch on November 4 ZURICH/GDANSK, Nov 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS NOVARTIS AG NOVN.S CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper CRISPR THERAPEUTICS AG CRSP.BN Third quarter results due. ANALYSTS' VIEWS BACHEM HOLDING AG BANB.S - JP MORGAN INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE CHF 86 ECONOMY SNB data on Swiss sight deposits due at 0900 GMT.
N

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper ZURICH, Nov 2 (Reuters) - Novartis NOVN.S expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from the end of patent protection on some drugs.
N

Biogen lifts annual profit forecast as new treatments boost earnings

UPDATE 2-Biogen lifts annual profit forecast as new treatments boost earnings Updates shares, adds analyst comment in paragraph 4, CEO comment in paragraph 7 and graphic By Mariam Sunny Oct 30 (Reuters) - Biogen BIIB.O raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
B
N

Swiss stocks - Factors to watch on October 30

Swiss stocks - Factors to watch on October 30 ZURICH/GDANSK, Oct 30 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: SWISS NATIONAL BANK The Swiss National Bank could further cut interest rates to maintain price stability, Chairman Martin Schlegel said on Tuesday. NOVARTIS NOVN.S Novartis says Scemblix FDA approved in newly diagnosed CML UBS UBSG.S UBS reports $1.4 bln net profit attributable to shareholders in Q3 COMPANY STATEMENTS SANDOZ SDZ.S Nine month
C
K
N
U

Asia Morning Call-Global Markets

UPDATE 1-Asia Morning Call-Global Markets Oct 30 (Reuters) - Stock Markets closing level) Net Chng Stock Markets Net Chng S&P/ASX 200** 8249.2 +27.7 NZX 50** 12783.36 +11.75 DJIA 42233.05 -154.52 NIKKEI** 38903.68 +298.15 Nasdaq 18712.748 +145.559 FTSE** 8219.61 -66.01 S&P 500 5832.92 +9.4 Hang Seng** 20701.14 +101.78 SPI 200 Fut 8268 -7 STI** 3590.36 +6.28 SSEC** 3286.407 -35.7905 KOSPI** 2617.8 +5.37 ---------------------------------------------------------------------------------------- Bonds
A
A
G
N
U
U
J
U
U

Novartis Says Scemblix FDA Approved In Newly Diagnosed CML, Offering Superior Efficacy, And Favorable Safety And Tolerability Profile

BRIEF-Novartis Says Scemblix FDA Approved In Newly Diagnosed CML, Offering Superior Efficacy, And Favorable Safety And Tolerability Profile Oct 29 (Reuters) - Novartis AG NOVN.S : NOVARTIS SCEMBLIX® FDA APPROVED IN NEWLY DIAGNOSED CML, OFFERING SUPERIOR EFFICACY, AND FAVORABLE SAFETY AND TOLERABILITY PROFILE NOVARTIS AG - SCEMBLIX SHOWS SUPERIOR E
N

Asia Morning Call-Global Markets

Asia Morning Call-Global Markets Oct 30 (Reuters) - Stock Markets Net Chng Stock Markets Net Chng S&P/ASX 200** 8249.2 +27.7 NZX 50** 12783.36 +11.75 DJIA 42337.77 -49.67 NIKKEI** 38903.68 +298.15 Nasdaq 18729.389 +162.2 FTSE** 8219.61 -66.01 S&P 500 5844.64 +21.12 Hang Seng** 20701.14 +101.78 SPI 200 Fut 8278 +3 STI** 3590.36 +6.28 SSEC** 3286.407 -35.7905 KOSPI** 2617.8 +5.37 ---------------------------------------------------------------------------------------- Bonds Bonds JP 10 YR Bond 0.97
A
A
G
N
U
U
J
U
U
U

FDA Grants Accelerated Approval To Asciminib For Newly Diagnosed Chronic Myeloid Leukemia

BRIEF-FDA Grants Accelerated Approval To Asciminib For Newly Diagnosed Chronic Myeloid Leukemia Oct 29 (Reuters) - FDA: FDA GRANTS ACCELERATED APPROVAL TO ASCIMINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA FDA: GRANTED ACCELERATED APPROVAL TO ASCIMINIB (SCEMBLIX, NOVARTIS AG) Further company coverage: NOVN.S
N

Novartis AG reports results for the quarter ended in September 30 - Earnings Summary

Novartis AG reports results for the quarter ended in September 30 - Earnings Summary Novartis AG NOVN.S reported quarterly adjusted earnings of $2.06​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.83. The mean expectation of ten analysts for the quarter was for earnings of $1.95 per share.
N

Novartis falls despite upbeat Q3, analysts cite individual drugs' performance

BUZZ-Novartis falls despite upbeat Q3, analysts cite individual drugs' performance Recasts with negative share reaction and analyst comments ** Shares in Swiss pharmaceutical group Novartis NOVN.S fall 3.4% after being indicated to rise in premarket trade, following a Q3 beat and outlook hike ** Vontobel analyst Stefan Schneider points to impairment charges for newly-acquired Morphosys MORG.S and a miss in U.S.
B
M
N



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.